Certain Common Stock of StemCell Institute Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2021.
September 21, 2021
Share
Certain Common Stock of StemCell Institute Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2021. These Common Stock will be under lockup for 89 days starting from 25-JUN-2021 to 22-SEP-2021.
Details:
Trim Medical Holdings Inc., the seller and lender, Shigemi Wakamatsu, the seller, and Nagoya Small and Medium Enterprise Investment Development Co., Ltd., Masanori Mori, the shareholders of the Company, in connection with this offer and the sale by the underwriter's purchase transaction. , Shino Cell Technologies, Inc., Kiyoaki Tomo, Daisuke Nogami, Koji Morisaki, Akiyoshi Urano, Yoshiko Kuwahara, Kazuya Suzuki, Ryoji Fukada, Kozo Shimura, Kazunori Yamada, Tatsuro Nishihara, Ryozo Fujii, Sayaka Kubo, Hiroshi Segawa, Sumi Matsumine , Shinhiro Sugawara, Hiroshi Kishi, Satoshi Tsuchiyama and Kazumasa Mori announced to the lead managing underwriter on September 22, 2021 on the 90th day after the listing (start of trading) date (including the day) from the date of signing the original underwriting contract. During the period up to the date, without the prior written consent of the lead managing underwriter, the sale of the Company's shares, etc. (however, the sale of the Company's common stock for sale by the underwriter's purchase transaction, the sale by over-allotment, and the lending of the Company's common stock We have agreed not to acquire the Company's common stock, which is subject to the Green Shoe Option, by the lead managing underwriter.)
In addition, the Company will inform the lead managing underwriter in advance of the lead managing underwriter during the period from the date of conclusion of the principal underwriting contract to December 21, 2021, which is the 180th day after the listing (starting of trading) date (including the day). Issuance of shares of the Company, issuance of securities converted or exchanged for the shares of the Company, or issuance of securities granted the right to acquire or receive the shares of the Company, etc. We have agreed not to issue stock acquisition rights as stock options.)
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.